Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells

Journal of Immunology

Volumn 177, Issue 9, 2006, Pages 6018-6024

  Dolan, Brian P ^a   Gibbs Jr , Kenneth D ^a   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL STRAIN 3T3; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; GENETIC TRANSFECTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

EID: 33750341482     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.9.6018     Document Type: Article

References (37)

1. Zinkernagel, R. M. 2002. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32: 2385-2392.
2. Rock, K. L., and L. Shen. 2005. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207: 166-183.
3. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143: 1283-128.
4. Ackerman, A. L., and P. Cresswell. 2004. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol. 5: 678-684.
5. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64.
6. Kundig, T. M., M. F. Bachmann, C. DiPaolo, J. J. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, et al. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268: 1343-1347.
7. Cayeux, S., G. Richter, C. Becker, A. Pezzutto, B. Dorken, and T. Blankenstein. 1999. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol. 29: 225-234.
8. Sigal, L. J., and K. L. Rock. 2000. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J. Exp. Med. 192: 1143-1150.
9. Sigal, L. J., S. Crotty, R. Andino, and K. L. Rock. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398: 77-80.
10. + dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172: 1996-2000.
11. + dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J. Immunol. 170: 4437-4440.
12. + T cells by infected dendritic cells in vivo. Nat. Immunol. 3: 265-271.
13. Freigang, S., D. Egger, K. Bienz, H. Hengartner, and R. M. Zinkernagel. 2003. Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming. Proc. Natl. Acad. Sci. USA 100: 13477-13482.
14. Norbury, C. C., and L. J. Sigal. 2003. Cross priming or direct priming: is that really the question? Curr. Opin. Immunol. 15: 82-88.
15. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
16. Huang, A. Y., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky. 1996. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 4: 349-355.
17. + T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200: 297-306.
18. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.
19. + T cell, responses. J. Immunol. 167: 3577-3584.
20. + T cells are activated by "cross- dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J. Immunol. 176: 1447-1455.
21. + cytotoxic T lymphocyte that mediate specific tumor rejection. J. Immunol. 151: 6283-6290.
22. Qi, L., and S. Ostrand-Rosenberg. 2000. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. Traffic 1: 152-160.
23. Shen, L., and K. L. Rock. 2004. Cellular protein is the source of cross-priming antigen in vivo. Proc. Natl. Acad. Sci. USA 101: 3035-3040.
24. Blok, R., D. H. Margulies, L. Pease, R. K. Ribaudo, J. Schneck, and J. McCluskey. 1992. CD8 expression alters the fine specificity of an alloreactive MHC class I-specific T hybridoma. Int. Immunol. 4: 455-466.
25. Catipovic, B., J. Dal Porto, M. Mage, T. E. Johansen, and J. P. Schneck. 1992. Major histocompatibility complex conformational epitopes are peptide specific. J. Exp. Med. 176: 1611-168.
26. Dolan, B. P., T. P. Phelan, D. Ilkovitch, L. Qi, W. F. Wade, T. M. Laufer, and S. Ostrand-Rosenberg. 2004. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines. J. Immunol. 172: 907-914.
27. Morris, E. J., and H. M. Geller. 1996. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J. Cell Biol. 134: 757-770.
28. + T lymphocytes provided they do not coexpress invariant chain. Cancer Immunol. Immunother. 53: 525-532.
29. Liu, Z., Q. Liu, H. Hamed, R. M. Anthony, A. Foster, F. D. Finkelman, J. F. Urban, Jr., and W. C. Gause. 2005. IL-2 and autocrine IL-4 drive the in vivo development of antigen-specific Th2 T cells elicited by nematode parasites. J. Immunol. 174: 2242-229.
30. Hsu, D. H., P. Paz, G. Villaflor, A. Rivas, A. Mehta-Damani, E. Angevin, L. Zitvogel, and J. B. Le Pecq. 2003. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J. Immunother. 26: 440-450.
31. Chaput, N., N. E. Schartz, F. Andre, J. Taieb, S. Novault, P. Bonnaventure, N. Aubert, J. Bernard, F. Lemonnier, M. Merad, et al. 2004. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. 172: 2137-2146.
32. Andre, F., N. Chaput, N. E. Schartz, C. Flament, N. Aubert, J. Bernard, F. Lemonnier, G. Raposo, B. Escudier, D. H. Hsu, et al. 2004. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 172: 2126-2136.
33. + T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23: 651-682.
34. + T cell cross-priming via transfer of proteasome substrates. Science 304: 1318-1321.
35. + T cells by exogenous cell-associated antigens. Immunity 17: 211-220.
36. + T cell response to a subdominant tumor antigen epitope. J. Immunol. 175: 700-712.
37. Wolkers, M. C., N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. Schumacher. 2004. Antigen bias in T cell cross-priming. Science 304: 1314-1317.